/Companies

Veritas In Silico

Kawasaki, JP · Founded 2016 · 15 employees on LinkedIn · 5 known investors

Find your way into Veritas In Silico

Sign up to see every warm intro you have to Veritas In Silico

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Veritas In Silico team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.

Founders & leadership

SNShingo Nakamura
Shingo NakamuraCEOShingo Nakamura holds a doctorate in synthetic organic chemistry from Nagoya University and has conducted postdoctoral research in molecular biology at Yale University. He spent seven years as a principal investigator at Takeda Pharmaceutical Company, followed by roles in sales and business development at Dow Chemical Company and Catalent Pharma Solutions, with additional academic affiliations at Japanese universities.

Investors · 5

In the news

Frequently asked questions

What does Veritas In Silico do?
Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.
Who are Veritas In Silico's investors?
Veritas In Silico's investors include Global Brain, KDDI Open Innovation Fund, Nippon Venture Capital, Shinsei Capital Partners, SMBC Venture Capital.
Where is Veritas In Silico headquartered?
Veritas In Silico is headquartered in Kawasaki, JP.